Composition for pulmonary administration comprising a drug and a hydrophobic amino acid
원문보기
IPC분류정보
국가/구분
United States(US) Patent
등록
국제특허분류(IPC7판)
A61K-009/14
A61K-009/50
A61K-038/00
출원번호
US-0355578
(2003-01-31)
발명자
/ 주소
Platz, Robert M.
Patton, John S.
Foster, Linda
Eljamal, Mohammed
출원인 / 주소
Nektar Therapeutics
인용정보
피인용 횟수 :
68인용 특허 :
143
초록▼
According to the subject invention, dispersible dry powder pharmaceutical-based compositions are provided, including methods for their manufacture and dry powder dispersion devices. A dispersible dry powder pharmaceutical-based composition is one having a moisture content of less than about 10% by w
According to the subject invention, dispersible dry powder pharmaceutical-based compositions are provided, including methods for their manufacture and dry powder dispersion devices. A dispersible dry powder pharmaceutical-based composition is one having a moisture content of less than about 10% by weight (% w) water, usually below about 5% w and preferably less than about 3% w; a particle size of about 1.0-5.0 μm mass median diameter (MMD), usually 1.0-4.0 μm MMD, and preferably 1.0-3.0 μm MMD; a delivered dose of about >30%, usually >40%, preferably >50%, and most preferred >60%; and an aerosol particle size distribution of about 1.0-5.0 μm mass median aerodynamic diameter (MMAD), usually 1.5-4.5 μm MMAD, and preferably 1.5-4.0 μm MMAD. Such compositions are of pharmaceutical grade purity.
대표청구항▼
1. A dispersible dry powder composition for pulmonary delivery, said composition comprising a therapeutically effective amount of a drug and a hydrophobic amino acid, Wherein about 95% of the mass of the dry powder composition has a particle size of less than 10 μm.2. The dry powder composition of c
1. A dispersible dry powder composition for pulmonary delivery, said composition comprising a therapeutically effective amount of a drug and a hydrophobic amino acid, Wherein about 95% of the mass of the dry powder composition has a particle size of less than 10 μm.2. The dry powder composition of claim 1, further comprising a pharmaceutically acceptable carrier.3. The dry powder composition of claim 1, wherein the hydrophobic amino acid is selected from the group consisting of tryptophan, tyrosine, leucine, and phenylalanine.4. The dry powder composition of claim 1, substantially free from penetration enhancers.5. The dry powder composition of claim 2, wherein the carrier comprises human serum albumin.6. The dry powder composition of claim 2, wherein the carrier comprises a carbohydrate bulking agent.7. The dry powder composition of claim 1, wherein about 80% of the mass of the dry powder composition has a particle size of less than 5 μm.8. The dry powder composition of claim 1, wherein the drug is a macromolecule.9. The dry powder composition of claim 1, wherein the drug is a non-macromolecule.10. The dry powder composition of claim 3, wherein said hydrophobic amino acid is lecuine.11. The dry powder composition of claim 1, wherein said dry powder composition particles having an aerosol particle size distribution of from about 1.0 to 5.0 μm MMAD.12. The dry powder composition of claim 1, wherein the dry powder is characterized by a delivered dose of greater than about 30%.13. The dry powder composition of claim 8, wherein the macromolecule is selected from the group consisting of insulin, interleukin 1 receptor, parathyroid hormone, alpha-1 antitrypsin, calcitonin, interferon, low molecular weight heparin, and nucleic acids.14. A unit dosage form for pulmonary delivery of a pharmaceutical drug, said unit dosage form comprising a dispersible dry powder composition, comprising a therapeutically effective amount of the pharmaceutical drug in combination with a hydrophobic amino acid according to any one of claims 1, 2, 3, 10, or 11.15. A spray-dried, dispersible dry powder composition for pulmonary delivery, said composition comprising a therapeutically effective amount of a drug and a hydrophobic amino acid, where about 95% of the mass of the dry powder composition has a particle size of less than 10 μm.
연구과제 타임라인
LOADING...
LOADING...
LOADING...
LOADING...
LOADING...
이 특허에 인용된 특허 (143)
Dunlap Richard P. (Penfield NY) Hlasta Dennis J. (Clifton Park NY) Desai Ranjit C. (Colonie NY) Latimer Lee H. (Brighton NY) Subramanyam Chakrapani (East Greenbush NY) Court John J. (Colonie NY) Bell, 2-saccharinylmethyl heterocyclic carboxylates useful as proteolytic enzyme inhibitors and compositions and method of use.
Edwards David A. ; Caponetti Giovanni,ITX ; Hrkach Jeffrey S. ; Lotan Noah,ILX ; Hanes Justin ; Ben-Jebria Abdell Aziz ; Langer Robert S., Aerodynamically light particles for pulmonary drug delivery.
Edwards David A. ; Caponetti Giovanni,ITX ; Hrkach Jeffrey S. ; Lotan Noah,ILX ; Hanes Justin ; Ben-Jebria Abdell Aziz ; Langer Robert S., Aerodynamically light particles for pulmonary drug delivery.
Evans Richard M. (Westwood MA) Farr Stephen J. (Llandaf GB7), Aerosol formulations including proteins and peptides solubilized in reverse micelles and process for making the aerosol.
Arora Vijay K. (Montvale NJ) Jones Gary V. (Bremen NJ DEX) Kovtun John M. (Rahway NJ) Brandlein Lawrence S. (Englishtown NJ), Coffee flakes and process.
Wang Yu-chang J. (Los Altos CA) Lee William A. (Los Altos CA) Narog Blair (Palo Alto CA), Composition and method for administration of pharmaceutically active substances.
Carpenter John F. (David CA) Hand Steven C. (Louisville CO) Crowe Lois M. (Davis CA) Crowe John H. (Davis CA), Cryogenic protection of phosphofructokinase using amino acids and zinc ions.
Andersson Jan A. R. (S. Sandby SEX) Nilsson Nils G. (Lund SEX) Fagerstrm Per-Olof S. (Bjrred SEX) Wendel Thomas M. (Genarp SEX), Device in connection with an inhaler.
Newell Robert E. (Pinner GB2) Rand Paul K. (Nitchin GB2) Fitzsimmons Robert A. (Barnard Castle GB2), Devices for administering medicaments to patients.
Platz Robert M. ; Patton John S. ; Foster Linda C. ; Eljamal Mohammed,LBX, Dispersible antibody compositions and methods for their preparation and use.
Cohen Smadar (Petach-Tickva ILX) Bano Carmen (Valencia PA ESX) Visscher Karyn B. (State College PA) Chow Marie (Brookline MA) Allcock Harry R. (State College PA) Langer Robert S. (Newton MA), Ionically cross-linked polymeric microcapsules.
Chien Yie W. (North Brunswick NJ) Kong-Jiann Li John (Plainsboro NJ) Liu Jue-Chen (East Brunswick NJ) Shi Wei-Min (Piscataway NJ) Siddiqui Ovais (Piscataway NJ) Sun Ying (King of Prussia PA), Iontotherapeutic device and process and iontotherapeutic unit dose.
Zoltan Bart J. (Old Tappan NJ) Laube Beth L. (Baltimore MD) Adams ; III George K. (Baltimore MD) Bow Clark F. (Newton NJ) Devito Ralph J. (Stanhope NJ) Harrington Walter (Flanders NJ) Hoffman Louis S, Medication delivery system phase two.
Smith Adrian E. ; Burr John D. ; Etter Jeffery W. ; Axford George S. ; Lyons Shirley W. ; Platz Robert M., Method and apparatus for dispersion of dry powder medicaments.
Platz Robert M. ; Kimura Shigenobu,JPX ; Satoh Yu-ichiro,JPX ; Foster Linda C., Methods and compositions for the dry powder formulation of interferons.
Boyes Robert N. (St. Albans AL GB2) Tice Thomas R. (Birmingham AL) Gilley Richard M. (Birmingham AL) Pledger Kenneth L. (Huntsville AL), Pharmaceutical formulations comprising microcapsules.
Edwards David A. ; Caponetti Giovanni ; Hrkach Jeffrey S. ; Lotan Noah,ILX ; Hanes Justin ; Langer Robert S. ; Ben-Jebria Abdellaziz, Porous particles for deep lung delivery.
Brenner Joseph (Middletown NY) Henderson Gary H. (Middletown NY) Bergensten Robert W. (Kerhonkson NY), Process of encapsulating an oil and product produced thereby.
Sarin Virender K. (Libertyville IL) Fox Jack L. (Lake Bluff IL) Gupta Shanker L. (Vernon Hills IL) Absolom Darryl R. (Columbus OH), Pulmonary surfactant protein fragments.
Hlasta Dennis J. (Lower Salford Township ; Montgomery County PA) Ackerman James H. (Albany NY) Mura Albert J. (Rochester NY) Desai Ranjit C. (Towamencin Township ; Montgomery County PA), Saccharin derivative proteolytic enzyme inhibitors.
Knight Jack V. (Houston TX) Wilson ; Jr. Samuel Z. (Houston TX), Small particle aerosol generator for treatment of respiratory disease including the lungs.
Knight Jack V. (Houston TX) Gilbert Brian E. (Houston TX) Wilson Samuel Z. (Houston TX) Six Howard R. (East Stroudsborg PA) Wyde Philip R. (Houston TX), Small particle aerosol liposome and liposome-drug combinations for medical use.
Dower Steven K. (Redmond WA) March Carl J. (Bainbridge Island WA) Sims John E. (Seattle WA) Urdal David L. (Seattle WA), Soluble human interleukin-1 receptors, compositions and method of use.
Bokovi Marijan A. (Ridgefield CT) Vidal Susan M. (Patterson NY) Saleeb Fouad Z. (Pleasantville NY), Spray-dried fixed flavorants in a carbohydrate substrate and process.
Feldman Fred (Park Forest IL) Klekamp Mark S. (Bourbonnais IL) Hrinda Michael E. (Gwynedd Valley PA) Shaw Arthur B. (Audubon PA) Chandra Sudhish (Kankakee IL), Stabilization of biological and pharmaceutical products during thermal inactivation of viral and bacterial contaminants.
Bckstrm Kjell G. E. (Lund SEX) Dahlbck Carl M. O. (Lund SEX) Edman Peter (Bjrred SEX) Johansson Ann C. B. (Lund SEX), Systemic administration of a therapeutic preparation.
Bckstrm Kjell G. E. (Lund SEX) Dahlbck Carl M. O. (Lund SEX) Edman Peter (Bjrred SEX) Johansson Ann C. B. (Lund SEX), Therapeutic preparation for inhalation.
Sakon Kiyoyuki,JPX ; Sakagami Masahiro,JPX ; Makino Yuji,JPX ; Suzuki Yoshiki,JPX ; Kobayashi Hideki,JPX, Ultrafine particle power for inhalation and method for production thereof.
Lander, Cynthia; Brophy, Colleen, Compositions and methods for preventing or treating diseases, conditions, or processes characterized by aberrant fibroblast proliferation and extracellular matrix deposition.
Lander, Cynthia; Brophy, Colleen, Compositions and methods for preventing or treating diseases, conditions, or processes characterized by aberrant fibroblast proliferation and extracellular matrix deposition.
Jung, Edward K. Y.; Levien, Royce A.; Lord, Robert W.; Malamud, Mark A.; Rinaldo, Jr., John D.; Wood, Jr., Lowell L., Computational and/or control systems and methods related to nutraceutical agent selection and dosing.
Jung, Edward K. Y.; Levien, Royce A.; Lord, Robert W.; Malamud, Mark A.; Rinaldo, Jr., John D.; Tegreene, Clarence T.; Wood, Jr., Lowell L., Computational systems and methods related to nutraceuticals.
Yuan, Rui Rong; Li, Wei Ping; Maeda, Yasuhiro; Dowling, Peter C., Erythropoietin-derived short peptide and its mimics as immuno/inflammatory modulators.
Yuan, Rui Rong; Li, Wei Ping; Maeda, Yasuhiro; Dowling, Peter C., Erythropoietin-derived short peptide and its mimics as immuno/inflammatory modulators.
Tarara, Thomas E.; Weers, Jeffry G.; Eldon, Michael A.; Narashimhan, Rangachari; Clark, Andrew, Formulation for pulmonary administration of antifungal agents, and associated methods of manufacture and use.
Jung, Edward K. Y.; Levien, Royce A.; Lord, Robert W.; Malamud, Mark A.; Rinaldo, Jr., John D.; Wood, Lowell L., Individualized pharmaceutical selection and packaging.
Tezapsidis, Nikolaos; Greco, Steven J.; Smith, Mark, Leptin compositions and methods for treating progressive cognitive function disorders resulting from accumulation of neurofibrillary tangles and amyloid beta.
Jung, Edward K. Y.; Levien, Royce A.; Lord, Robert W.; Malamud, Mark A.; Rinaldo, Jr., John D.; Tegreene, Clarence T.; Wood, Jr., Lowell L., Methods and systems related to receiving nutraceutical associated information.
Jung, Edward K. Y.; Levien, Royce A.; Lord, Robert W.; Malamud, Mark A.; Rinaldo, Jr., John D.; Tegreene, Clarence T.; Wood, Jr., Lowell L., Methods and systems related to transmission of nutraceutical associated information.
Wang, Bo; Yuan, Rui Rong; Lu, Wei; Dowling, Peter C., Methods for treating inflammatory disorders and traumatic brain injury using stabilized non-hematopoietic EPO short peptides.
Pilkiewicz, Frank G.; Perez-Soler, Roman; Zou, Yiyu; Perkins, Walter R.; Lee, Jin K.; Malinin, Vladimir, Methods of treating cancer with high potency lipid-based platinum compound formulations administered intraperitoneally.
Tarara, Thomas E.; Weers, Jeffrey G.; Kabalnov, Alexey; Schutt, Ernest G.; Dellamary, Luis A., Pulmonary delivery particles comprising an active agent.
Dellamary, Luis A.; Reiss, Jean; Schutt, Ernest G.; Weers, Jeffry G.; Tarara, Thomas E., Stable metal ion-lipid powdered pharmaceutical compositions for drug delivery.
Dellamary, Luis A.; Riess, Jean; Schutt, Ernest G.; Weers, Jeffry G.; Tarara, Thomas E., Stable metal ion-lipid powdered pharmaceutical compositions for drug delivery and methods of use.
Dellamary, Luis A; Riess, Jean; Schutt, Ernest G; Weers, Jeffry G; Tarara, Thomas E, Stable metal ion-lipid powdered pharmaceutical compositions for drug delivery and methods of use.
Jung, Edward K. Y.; Leuthardt, Eric C.; Levien, Royce A.; Lord, Robert W.; Malamud, Mark A.; Rinaldo, Jr., John D.; Wood, Jr., Lowell L., Systems and methods for transmitting pathogen related information and responding.
De Brabander, Jef; Shay, Jerry W.; Wang, Wentian; Nijhawan, Deepak; Theodoropoulos, Pano, Targeting emopamil binding protein (EBP) with small molecules that induce an abnormal feedback response by lowering endogenous cholesterol biosynthesis.
Lander, Cynthia; Brophy, Colleen; Peterson, Caryn; Luber, Andrew, Use of MKS inhibitor peptide-containing compositions for treating non-small cell lung cancer with same.
※ AI-Helper는 부적절한 답변을 할 수 있습니다.